메뉴 건너뛰기




Volumn 59, Issue 5, 2015, Pages 2882-2885

Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; EMTRICITABINE; LAMIVUDINE; LUCIFERASE; RNA DIRECTED DNA POLYMERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

EID: 84931287839     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05181-14     Document Type: Article
Times cited : (17)

References (34)
  • 1
    • 80051829496 scopus 로고    scopus 로고
    • Development of antiretroviral drug resistance
    • Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N Engl J Med 365:637-646. http://dx.doi.org/10.1056/NEJMra1004180.
    • (2011) N Engl J Med , vol.365 , pp. 637-646
    • Wainberg, M.A.1    Zaharatos, G.J.2    Brenner, B.G.3
  • 2
    • 84888099693 scopus 로고    scopus 로고
    • What if HIV were unable to develop resistance against a new therapeutic agent?
    • Wainberg MA, Mesplede T, Raffi F. 2013. What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med 11:249. http://dx.doi.org/10.1186/1741-7015-11-249.
    • (2013) BMC Med , vol.11 , pp. 249
    • Wainberg, M.A.1    Mesplede, T.2    Raffi, F.3
  • 5
    • 84885948765 scopus 로고    scopus 로고
    • Oncedaily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 Week results from a randomised, double-blind, non-inferiority trial
    • Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S. 2013. Oncedaily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13:927-935. http://dx.doi.org/10.1016/S1473-3099(13)70257-3.
    • (2013) Lancet Infect Dis , vol.13 , pp. 927-935
    • Raffi, F.1    Jaeger, H.2    Quiros-Roldan, E.3    Albrecht, H.4    Belonosova, E.5    Gatell, J.M.6    Baril, J.G.7    Domingo, P.8    Brennan, C.9    Almond, S.10    Min, S.11
  • 6
    • 84903303497 scopus 로고    scopus 로고
    • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 Week results from the randomised open-label phase 3b study
    • Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S, ING114915 Study Team. 2014. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383:2222-2231. http://dx.doi.org/10.1016/S0140-6736(14)60084-2.
    • (2014) Lancet , vol.383 , pp. 2222-2231
    • Clotet, B.1    Feinberg, J.2    Van Lunzen, J.3    Khuong-Josses, M.A.4    Antinori, A.5    Dumitru, I.6    Pokrovskiy, V.7    Fehr, J.8    Ortiz, R.9    Saag, M.10    Harris, J.11    Brennan, C.12    Fujiwara, T.13    Min, S.14
  • 7
    • 84931262441 scopus 로고    scopus 로고
    • Integrase strand transfer inhibitors in HIV therapy
    • Mesplede T, Wainberg M. 2013. Integrase strand transfer inhibitors in HIV therapy. Infect Dis Ther 2:83-93. http://dx.doi.org/10.1007/s40121-013-0020-8.
    • (2013) Infect Dis Ther , vol.2 , pp. 83-93
    • Mesplede, T.1    Wainberg, M.2
  • 8
    • 84894503546 scopus 로고    scopus 로고
    • A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results
    • Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, Zolopa A, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J, GS-US-236-0102 Study Team. 2014. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 65:e118-e120. http://dx.doi.org/10.1097/QAI.0000000000000057.
    • (2014) J Acquir Immune Defic Syndr , vol.65 , pp. e118-e120
    • Wohl, D.A.1    Cohen, C.2    Gallant, J.E.3    Mills, A.4    Sax, P.E.5    Dejesus, E.6    Zolopa, A.7    Liu, H.C.8    Plummer, A.9    White, K.L.10    Cheng, A.K.11    Rhee, M.S.12    Szwarcberg, J.13
  • 9
    • 84155164041 scopus 로고    scopus 로고
    • Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study
    • Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL. 2012. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 12:27-35. http://dx.doi.org/10.1016/S1473-3099(11)70249-3.
    • (2012) Lancet Infect Dis , vol.12 , pp. 27-35
    • Molina, J.M.1    Lamarca, A.2    Andrade-Villanueva, J.3    Clotet, B.4    Clumeck, N.5    Liu, Y.P.6    Zhong, L.7    Margot, N.8    Cheng, A.K.9    Chuck, S.L.10
  • 10
    • 84870533547 scopus 로고    scopus 로고
    • Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial
    • Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F. 2013. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med 14:49-59. http://dx.doi.org/10.1111/j.1468-1293.2012.01060.x.
    • (2013) HIV Med , vol.14 , pp. 49-59
    • Orkin, C.1    DeJesus, E.2    Khanlou, H.3    Stoehr, A.4    Supparatpinyo, K.5    Lathouwers, E.6    Lefebvre, E.7    Opsomer, M.8    Van De Casteele, T.9    Tomaka, F.10
  • 11
    • 84863393356 scopus 로고    scopus 로고
    • Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
    • Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
    • (2012) J Virol , vol.86 , pp. 2696-2705
    • Quashie, P.K.1    Mesplede, T.2    Han, Y.S.3    Oliveira, M.4    Singhroy, D.N.5    Fujiwara, T.6    Underwood, M.R.7    Wainberg, M.A.8
  • 12
    • 84897975407 scopus 로고    scopus 로고
    • Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
    • Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. 2014. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 28:813-819. http://dx.doi.org/10.1097/QAD.0000000000000199.
    • (2014) AIDS , vol.28 , pp. 813-819
    • Oliveira, M.1    Mesplede, T.2    Quashie, P.K.3    Moisi, D.4    Wainberg, M.A.5
  • 14
    • 84907429695 scopus 로고    scopus 로고
    • Is resistance to dolutegravir possible when this drug is used in first-line therapy?
    • Mesplede T, Wainberg MA. 2014. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses 6:3377-3385. http://dx .doi.org/10.3390/v6093377.
    • (2014) Viruses , vol.6 , pp. 3377-3385
    • Mesplede, T.1    Wainberg, M.A.2
  • 16
    • 84892453291 scopus 로고    scopus 로고
    • The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
    • Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. http://dx.doi.org/10.1186/1742-4690-11-7.
    • (2014) Retrovirology , vol.11 , pp. 7
    • Wares, M.1    Mesplede, T.2    Quashie, P.K.3    Osman, N.4    Han, Y.5    Wainberg, M.A.6
  • 17
    • 84908253044 scopus 로고    scopus 로고
    • Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity
    • Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. 2014. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 69:2733-2740. http://dx.doi.org/10.1093/jac/dku199.
    • (2014) J Antimicrob Chemother , vol.69 , pp. 2733-2740
    • Mesplede, T.1    Osman, N.2    Wares, M.3    Quashie, P.K.4    Hassounah, S.5    Anstett, K.6    Han, Y.7    Singhroy, D.N.8    Wainberg, M.A.9
  • 19
    • 0029885139 scopus 로고    scopus 로고
    • Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins
    • Keulen W, Boucher C, Berkhout B. 1996. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res 31:45-57. http://dx.doi.org/10.1016/0166-3542(96)00944-8.
    • (1996) Antiviral Res , vol.31 , pp. 45-57
    • Keulen, W.1    Boucher, C.2    Berkhout, B.3
  • 21
    • 0037118912 scopus 로고    scopus 로고
    • M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine
    • Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M, CNA3002 International Study Team. 2002. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 16:1686-1689. http://dx.doi.org/10.1097/00002030-200208160-00017.
    • (2002) AIDS , vol.16 , pp. 1686-1689
    • Ait-Khaled, M.1    Stone, C.2    Amphlett, G.3    Clotet, B.4    Staszewski, S.5    Katlama, C.6    Tisdale, M.7
  • 22
    • 0034851899 scopus 로고    scopus 로고
    • Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples
    • Miller MD, Margot NA, Hertogs K, Larder B, Miller V. 2001. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 20:1025-1028. http://dx.doi.org/10.1081/NCN-100002483.
    • (2001) Nucleosides Nucleotides Nucleic Acids , vol.20 , pp. 1025-1028
    • Miller, M.D.1    Margot, N.A.2    Hertogs, K.3    Larder, B.4    Miller, V.5
  • 23
    • 0034867418 scopus 로고    scopus 로고
    • Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations
    • Devereux HL, Emery VC, Johnson MA, Loveday C. 2001. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 65:218-224. http://dx.doi.org/10.1002/jmv.2023.
    • (2001) J Med Virol , vol.65 , pp. 218-224
    • Devereux, H.L.1    Emery, V.C.2    Johnson, M.A.3    Loveday, C.4
  • 24
    • 66149141029 scopus 로고    scopus 로고
    • OpenEpi: A web-based epidemiologic and statistical calculator for public health
    • Sullivan KM, Dean A, Soe MM. 2009. OpenEpi: a web-based epidemiologic and statistical calculator for public health. Public Health Rep 124:471-474.
    • (2009) Public Health Rep , vol.124 , pp. 471-474
    • Sullivan, K.M.1    Dean, A.2    Soe, M.M.3
  • 25
    • 84921962113 scopus 로고    scopus 로고
    • Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors
    • Hassounah SA, Mesplede T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA. 2014. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J Virol 88:9683-9692. http://dx.doi.org/10.1128/JVI.00947-14.
    • (2014) J Virol , vol.88 , pp. 9683-9692
    • Hassounah, S.A.1    Mesplede, T.2    Quashie, P.K.3    Oliveira, M.4    Sandstrom, P.A.5    Wainberg, M.A.6
  • 27
    • 0022495870 scopus 로고
    • Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
    • Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
    • (1986) J Virol , vol.59 , pp. 284-291
    • Adachi, A.1    Gendelman, H.E.2    Koenig, S.3    Folks, T.4    Willey, R.5    Rabson, A.6    Martin, M.A.7
  • 28
    • 0029063578 scopus 로고
    • Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1
    • Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, Reitz MS, Jr. 1995. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 69:3712-3720.
    • (1995) J Virol , vol.69 , pp. 3712-3720
    • Lusso, P.1    Cocchi, F.2    Balotta, C.3    Markham, P.D.4    Louie, A.5    Farci, P.6    Pal, R.7    Gallo, R.C.8    Reitz, M.S.9
  • 29
    • 0017710978 scopus 로고
    • Characteristics of a human cell line transformed by DNA from human adenovirus type 5
    • Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74. http://dx.doi.org/10.1099/0022-1317-36-1-59.
    • (1977) J Gen Virol , vol.36 , pp. 59-74
    • Graham, F.L.1    Smiley, J.2    Russell, W.C.3    Nairn, R.4
  • 30
    • 67749110262 scopus 로고    scopus 로고
    • Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1
    • Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 83:8289-8292. http://dx.doi.org/10.1128/JVI.00709-09.
    • (2009) J Virol , vol.83 , pp. 8289-8292
    • Platt, E.J.1    Bilska, M.2    Kozak, S.L.3    Kabat, D.4    Montefiori, D.C.5
  • 31
    • 57349139455 scopus 로고    scopus 로고
    • Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research
    • Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 82:12585-12588. http://dx.doi.org/10.1128/JVI.01726-08.
    • (2008) J Virol , vol.82 , pp. 12585-12588
    • Takeuchi, Y.1    McClure, M.O.2    Pizzato, M.3
  • 33
    • 0033856458 scopus 로고    scopus 로고
    • Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
    • Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74:8358-8367. http://dx.doi.org/10.1128/JVI.74.18.8358-8367.2000.
    • (2000) J Virol , vol.74 , pp. 8358-8367
    • Derdeyn, C.A.1    Decker, J.M.2    Sfakianos, J.N.3    Wu, X.4    O'Brien, W.A.5    Ratner, L.6    Kappes, J.C.7    Shaw, G.M.8    Hunter, E.9
  • 34
    • 0031954686 scopus 로고    scopus 로고
    • Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1
    • Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72:2855-2864.
    • (1998) J Virol , vol.72 , pp. 2855-2864
    • Platt, E.J.1    Wehrly, K.2    Kuhmann, S.E.3    Chesebro, B.4    Kabat, D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.